Kyprolis
Kyprolis ingredients
| Active ingredient | Strength |
|---|---|
| Carfilzomib | 60 mg/30mL, 10 mg/5mL, 30 mg/15mL |
What Kyprolis is used for
The FDA lists the approved uses on the official label (below). In the EU, carfilzomib is approved as Kyprolis for:
Kyprolis in combination with daratumumab and dexamethasone, with lenalidomide and dexamethasone, or with dexamethasone alone is indicated for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
EU wording from the European Medicines Agency; US approved uses can differ.
Key facts
- Brand
- Kyprolis
- Generic name
- Carfilzomib
- Made by
- Onyx Pharmaceuticals, Inc.
- Forms
- Injection, Powder, Lyophilized, For Solution
- Given
- Intravenous
- Drug class
- Proteasome Inhibitor
- FDA approval
- New drug application (NDA) NDA202714
- On the US market since
- 2012
Official information
- Kyprolis prescribing information (FDA label) on DailyMed
- MedlinePlus drug information (search for Carfilzomib)
In India
- Carfilzomib: 3 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Kyprolis?
Kyprolis (Carfilzomib) is a cancer medicine made by Onyx Pharmaceuticals, Inc., approved by the US FDA.
What are the ingredients of Kyprolis?
Kyprolis contains Carfilzomib (60 mg/30mL, 10 mg/5mL, 30 mg/15mL).
Is Kyprolis approved in Europe?
The same active substance is approved in the EU as Kyprolis.
From the FDA National Drug Code directory (open.fda.gov, public domain) and the European Medicines Agency medicines list. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, USA